Emcure Pharmaceuticals Ltd. appears to have thrown down the gauntlet to Eisai Co. Ltd. with the launch on the Indian market of its “cost-effective” generic version of the Japanese firm’s Halaven (eribulin) for the treatment of metastatic breast cancer (MBC).
Emcure’s eribulin (marketed as Eribilin), which the Indian firm claims is the world’s first generic version of Halaven, is priced at INR19,500 ($283